Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

The United States is seeing a second peak in flu cases this season. After doctor’s office visits for flu dipped early this ...

Pfizer tock edged lower Tuesday on a "pretty uneventful quarter" as revenue from its Covid products helped drive a fourth-quarter beat.

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer’s drug discovery and development ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The company’s ...

Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.

Today, Benzinga's options scanner spotted 33 options trades for Pfizer. This is not a typical pattern. The sentiment among these major traders is split, with 66% bullish and 33% bearish. Among all the ...